Drug Profile
Evodenoson
Alternative Names: ATL-313; DE-112Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Adenosine Therapeutics
- Developer PGxHealth; Santen Pharmaceutical
- Class Anti-inflammatories; Purine nucleosides; Small molecules
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Haematological malignancies; Multiple sclerosis; Neuropathic pain; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
- 01 Feb 2012 Santen completes the phase I/II trial in Glaucoma in USA (NCT01279083)